Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMOX1 | P09601 | 1/20 | 0.36 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.32 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.32 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.32 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.32 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.32 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.32 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | CACNA1E | Q15878 | 1/20 | 0.32 |
| ▸ | CACNA2D4 | Q7Z3S7 | 1/20 | 0.32 |
| ▸ | CACNA2D3 | Q8IZS8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719738 | 0.84 | PDE10A (0.39) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL632170 | 0.82 | PDE10A (0.36) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL718495 | 0.81 | PDE10A (0.42) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL18444799 | 0.79 | HMOX1 (0.43) | HMOX1 | |
| SCHEMBL26027820 | 0.79 | MMP1 (0.35) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL12525729 | 0.78 | HMOX1 (0.39) | HMOX1 | |
| SCHEMBL164350 | 0.76 | HMOX1 (0.42) | HMOX1 | |
| SCHEMBL256102 | 0.76 | HMOX1 (0.42) | HMOX1 | |
| SCHEMBL16691214 | 0.74 | HMOX1 (0.41) | HMOX1 | |
| SCHEMBL2016327 | 0.74 | EPHX2 (0.39) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419418-B1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-15 | — | — | EP | disclosed |
| EP-2419418-B1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-15 | — | — | EP | disclosed |
| US-8324186-B2 | 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-12-04 | — | — | US | disclosed |
| US-8324186-B2 | 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-12-04 | — | — | US | disclosed |
| US-8324186-B2 | 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-12-04 | — | — | US | disclosed |
| EP-2419418-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010121036-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267668-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267668-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267668-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267668-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | CCR2, CCR1, CXCR2 | HMOX1 739/4885CACNB4 4680/4885CACNA1A 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.